weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva, was the first vaccine approved by the US Food and Drug Administration to prevent disease ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

If granted, IXCHIQ ® will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025 – ...

NEW YORK CITY, NY / ACCESS Newswire / March 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.

Valneva has met its revenue growth target for 2024, fending off slower-than-expected sales for the chikungunya vaccine Ixchiq. The French vaccine specialist posted total revenues of €169.6m ($ ...

weakened version of the chikungunya virus. The vaccine, manufactured by the biotechnology company Valneva, was the first vaccine approved by the US Food and Drug Administration to prevent disease ...

This new agreement complements the license agreement Valneva signed in 2021 with Instituto Butantan in Brazil for the development, manufacturing and marketing of a local chikungunya vaccine at an ...